Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Researchers: Vertex's Kalydeco a big step, but combination approach may be leap

This article was originally published in Scrip

Executive Summary

While Vertex Pharmaceuticals' experimental cystic fibrosis (CF) drug Kalydeco (ivacaftor/VX-770), whose application currently is before the US FDA, has the potential to be the first marketed drug aimed at attacking the basic defect involved in the disease – marking one of the greatest strides forward in CF – researchers believe the next big step, and the one that will affect a broader population, is with its use as part of a combination therapy (scripintelligence, 20 October 2011).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts